Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,628,367
  • Shares Outstanding, K 41,114
  • Annual Sales, $ 286,630 K
  • Annual Income, $ -42,610 K
  • 36-Month Beta 1.55
  • Price/Sales 5.03
  • Price/Cash Flow 655.27
  • Price/Book 5.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.07
  • Number of Estimates 6
  • High Estimate 0.20
  • Low Estimate -0.17
  • Prior Year 0.18
  • Growth Rate Est. (year over year) -61.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.04 +6.94%
on 02/11/19
41.56 -4.69%
on 01/31/19
-0.43 (-1.07%)
since 01/18/19
3-Month
35.58 +11.33%
on 01/04/19
50.30 -21.25%
on 12/04/18
-7.12 (-15.24%)
since 11/21/18
52-Week
26.95 +46.98%
on 04/02/18
55.00 -27.98%
on 11/02/18
+9.46 (+31.38%)
since 02/21/18

Most Recent Stories

More News
Pacira to Report 2018 Financial Results on Thursday February 28, 2019

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2018 financial results before the open of the U.S. markets on Thursday, February...

PCRX : 39.61 (-1.59%)
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

PBYI : 26.13 (-2.32%)
LLY : 122.72 (+0.05%)
ACAD : 22.26 (-2.45%)
PCRX : 39.61 (-1.59%)
REPH : 8.40 (-2.21%)
EPZM : 11.72 (-4.09%)
BMY : 50.13 (-2.28%)
Why Pacira (PCRX) Could Beat Earnings Estimates Again

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PCRX : 39.61 (-1.59%)
Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings

Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.

HLF : 56.13 (-0.27%)
JAZZ : 125.21 (-1.24%)
DOVA : 7.46 (-2.61%)
PCRX : 39.61 (-1.59%)
Pacira Expands EXPAREL Manufacturing Capacity to Meet Growing Demand

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that commercial production of EXPAREL(R) (bupivacaine liposome injectable suspension) is now underway at a custom suite in Swindon, UK created...

PCRX : 39.61 (-1.59%)
Watch for Pacira Pharmaceu to Potentially Pullback After Gaining 2.42% Yesterday

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $39.67 to a high of $41.01. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high...

PCRX : 39.61 (-1.59%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Pacira Pharmaceu (PCRX , MNK , RVNC , OMER , AERI )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

MNK : 20.52 (-3.30%)
PCRX : 39.61 (-1.59%)
RVNC : 17.26 (-3.95%)
Pacira's Study on Exparel Label Expansion Meets Endpoints

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

MRK : 79.83 (+0.50%)
LLY : 122.72 (+0.05%)
ABBV : 78.75 (-1.55%)
PCRX : 39.61 (-1.59%)
EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL(bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its...

PCRX : 39.61 (-1.59%)
New Research Coverage Highlights LKQ, Pacira Pharmaceuticals, WellCare Health Plans, Masimo, Workday, and Potbelly -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LKQ Corporation (NASDAQ:LKQ),...

PBPB : 8.33 (-4.91%)
LKQ : 27.34 (+1.37%)
MASI : 128.81 (+0.02%)
WCG : 274.17 (-1.37%)
PCRX : 39.61 (-1.59%)
WDAY : 189.47 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PCRX with:

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 41.32
1st Resistance Point 40.46
Last Price 39.61
1st Support Level 38.88
2nd Support Level 38.16

See More

52-Week High 55.00
Fibonacci 61.8% 44.28
Fibonacci 50% 40.97
Last Price 39.61
Fibonacci 38.2% 37.67
52-Week Low 26.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar